

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements

for the year ended 28 February 2022

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Index

	Page
Directors' Responsibilities and Approval	2
Report of the Audit Committee	3
Statement of compliance by the company secretary	4
Independent Auditor's Report	5 - 7
Directors' Report	8 - 10
Statement of Profit or Loss and Other Comprehensive Income	11
Statement of Financial Position	12
Statement of Cash Flows	13
Statement of Changes in Equity	14
Accounting Policies	15 - 25
Notes to the Consolidated Annual Financial Statements	26 - 56

LEVEL OF ASSURANCE

These consolidated annual financial statements have been audited in compliance with the applicable requirements of the Companies Act of South Africa.

These financial statements were:

Prepared by: S R Mugova CA(SA)

Supervised by: N Gany CA(SA)

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Directors' Responsibilities and Approval

The directors are required by the Companies Act of South Africa to maintain adequate accounting records and are responsible for the content and integrity of the consolidated annual financial statements and related financial information included in this report. It is their responsibility to ensure that the consolidated annual financial statements satisfy International Financial Reporting Standards with regards to form and content, and present fairly the consolidated statement of financial position, results of operations and business of the Group, and explain the transactions and financial position of the business of the Group at the end of the financial year. The consolidated annual financial statements are based upon appropriate accounting policies consistently applied throughout the Group and supported by reasonable and prudent judgements and estimates.

The directors acknowledge that they are ultimately responsible for the system of internal financial control established by the Group and place considerable importance on maintaining a strong control environment. To enable the directors to meet these responsibilities, the directors set standards for internal control aimed at reducing the risk of error or loss in a cost effective manner. The standards include the proper delegation of responsibilities within a clearly defined framework, effective accounting procedures and adequate segregation of duties to ensure an acceptable level of risk. These controls are monitored throughout the Group and all employees are required to maintain the highest ethical standards in ensuring the Group's business is conducted in a manner that, in all reasonable circumstances, is above reproach.

The directors are of the opinion, based on the information and explanations given by management and the internal auditors, that the system of internal control provides reasonable assurance that the financial records may be relied on for the preparation of the consolidated annual financial statements. However, any system of internal financial control can provide only reasonable, and not absolute, assurance against material misstatement or loss. The going-concern basis has been adopted in preparing the consolidated annual financial statements. Based on forecasts and available cash resources the directors have no reason to believe that the Group will not be a going concern in the foreseeable future. The consolidated annual financial statements support the viability of the Group.

The focus of risk management in the Group is on identifying, assessing, managing and monitoring all known forms of risk across the Group. While operating risk cannot be fully eliminated, the Group endeavours to minimise it by ensuring that appropriate infrastructure, controls, systems and ethical behaviour are applied and managed within predetermined procedures and constraints.

The consolidated annual financial statements have been audited by the independent auditing firm, PKF Durban, who have been given unrestricted access to all financial records and related data, including minutes of all meetings of the shareholders, the directors and committees of the directors. The directors believe that all representations made to the independent auditor during the audit were valid and appropriate. The external auditor's unqualified audit report is presented on pages 5 to 7.

The consolidated annual financial statements set out on pages 11 to 56 which have been prepared on the going concern basis, were approved by the directors and were signed on 26 May 2022 on their behalf by:



Mr A Devchand
Chief Executive Officer



Mr F J Meiring
Chief Financial Officer

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Report of the Audit Committee


Report of the Audit Committee in terms of section 94(7)(f) of the Companies Act

The committee met on five occasions to carry out its function for the financial year and held further discussions with the external and internal auditors and management. Based on the information supplied at those meetings, the Audit Committee has no reason to believe that there were any material failures or breakdowns in the accounting practices and the system design and effectiveness of internal financial controls during the year.

The committee also satisfied itself on the independence of the external auditors and that they were properly appointed in terms of the Companies Act.

The committee reviewed the consolidated annual financial statements as well as the significant judgements and reporting decisions with the assurance providers and management and came to the conclusions that:

- The going concern basis of reporting is appropriate.
- The consolidated annual financial statements comply in all material respects with statutory and International Financial Reporting Standards disclosure requirements.
- The consolidated annual financial statements should be approved by the board and circulated to shareholders



Mr M G Meehan CA(SA)

Chairman of the Audit Committee

26 May 2022

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Statement of Compliance by the Company Secretary

I hereby certify, in my capacity as company secretary of Lenmed Investments Limited and its subsidiaries, that for the financial year ended 28 February 2022, the company has filed all required returns and notices in terms of the Companies Act of South Africa, with the Companies and Intellectual Property Commission and that all such returns and notices appear to the best of my knowledge and believe to be true, correct and up to date.



W.R. Somerville

Company Secretary

26 May 2022

Independent Auditor's Report

To the Shareholders of Lenmed Investments Limited

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Lenmed Investments Limited and its subsidiaries (the group) set out on pages 11 to 56, which comprise the consolidated statement of financial position as at 28 February 2022, and the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of Lenmed Investments Limited and its subsidiaries as at 28 February 2022, and its consolidated financial performance and consolidated cash flows for the year then ended in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the group in accordance with the Independent Regulatory Board for Auditors' *Code of Professional Conduct for Registered Auditors* (IRBA Code) and other independence requirements applicable to performing audits of financial statements in South Africa. We have fulfilled our other ethical responsibilities in accordance with the IRBA Code and in accordance with other ethical requirements applicable to performing audits in South Africa. The IRBA Code is consistent with the corresponding sections of the International Ethics Standards Board for Accountants' *International Code of Ethics for Professional Accountants (including International Independence Standards)*. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the document titled "Lenmed Investments Limited and its subsidiaries Consolidated Annual Financial Statements for the year ended 28 February 2022" and in the document titled "Lenmed Investments Limited Separate Annual Financial Statements for the year ended 28 February 2022", which includes the Directors' Report, the Audit Committee's Report and the Company Secretary's Certificate as required by the Companies Act of South Africa, which we obtained prior to the date of this report, and the document titled "Lenmed Investments Limited Annual Integrated Report 2022", which is expected to be made available to us after that date. The other information does not include the consolidated or the separate financial statements and our auditor's reports thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Consolidated Financial Statements

The directors are responsible for the preparation and fair presentation of the consolidated financial statements

in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible for assessing the group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements

In terms of the IRBA Rule published in Government Gazette Number 39475 dated 4 December 2015, we report that PKF Durban has been the auditor of Lenmed Investments Limited for 14 years.

PKF Durban
Partner: R.C. Boule
Registered Auditor
Durban
Date:

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Directors' Report

The directors present their report for the year ended 28 February 2022.

1. Review of financial results and activities

Main business and operations

The principal activities of the Group during the year were the provision of private patient health care, through management and ownership of hospitals and other related health care services. There were no major changes in the nature of the business during the year under review.

The operating results and consolidated statement of financial position of the Group are fully set out in the attached financial statements and further amplified in this report.

2. Group Financial Results

The Group's earnings before interest, taxation, depreciation and amortisation (EBITDA) amounted to R533.671 million (2021: R243.267 million).

Group's profit before taxation for the year amounted to R281.618 million (2021: (loss) R96.490 million) before taking into account taxation of R33.926 million (2021: (credit) R27.086 million), resulting in profit after taxation for the year of R247.692 million (2021: (loss) R69.404 million).

The results of the Group are set out in the attached consolidated annual financial statements. The separate annual financial statements of the company are presented apart from the consolidated annual financial statements and were approved by the directors on 26 May 2022, the same date as the consolidated annual financial statements. The consolidated annual financial statements have been prepared in accordance with International Financial Reporting Standards.

3. Authorised and issued share capital

No changes were approved or made to the authorised or issued share capital of the company during the year under review.

4. Borrowings

In terms of the Memorandum of Incorporation of the company, the directors may exercise all the powers of the company to borrow money, as they consider appropriate.

The directors did not exceed any authorised levels of borrowings as required in the Memorandum of incorporation or the Companies Act during the year under review.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Directors' Report

5. Dividend

The company revised its dividend policy during the year:

- a. A dividend of 10% of headline earnings attributable to Lenmed shareholders will be declared annually.
- b. Basis of dividend:
 - Only a final dividend will be declared and no interim dividend is to be paid.
 - The final dividend will be declared after the board has approved the audited consolidated annual financial statements for the year - normally in May in respect of the February financial year-end.
 - Payment of the dividend will be made by EFT, prior to the Annual General Meeting, which is usually held in August.
 - The declaration and payment of the dividend is subject to the Board completing the solvency and liquidity tests required in terms of Section 4 of the Companies Act and the approval of Lenmed's bankers in accordance with the debt funding terms and conditions.
- c. The Dividend policy shall be reviewed at least annually.

Headline earnings

Headline earnings are determined in accordance with the Headline Earnings Circular issued by the South African Institute of Chartered Accountants from time to time and effective as at year end.

6. Directors

The directors of the company during the year and up to the date of this report are as follows:

Mr P Devchand	Executive Chairman
Mr A Devchand	Executive director and Chief Executive Officer
Mr F J Meiring	Executive director and Chief Financial Officer
Mr M G Meehan	Lead independent non-executive director
Ms B Harie	Independent non-executive director
Ms N V Simamane	Independent non-executive director
Dr G Goolab	Independent non-executive director
Prof B D Goolab	Non-executive director
Mr V E Firman (Appointed 1 March 2022)	Non-executive director

7. Company Secretary

The Group's designated company secretary is Mr. W.R. Somerville.

8. Independent auditors

PKF Durban, Registered Auditors, will continue in office as external auditors of the company in accordance with section 90(1) of the Companies Act of South Africa, subject to shareholder approval at the upcoming Annual General Meeting. R.C. Boulle will be the individual registered auditor who will undertake the audit.

9. Events after reporting date

All events subsequent to the date of the consolidated annual financial statements and International Financial Reporting Standards which require adjustment or disclosure have been adjusted or disclosed.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Directors' Report

During May 2022, the Group entered into an agreement to acquire 100% of Matlosana Medical Health Services (Pty) Ltd (“MMHS”), a Klerksdorp based group of hospitals. MMHS consists of 2 acute facilities (218 beds), a day hospital (20 beds) and a mental health facility (50 beds). The acquisition aligns well with our strategy to diversify across geographies as well as revenue streams and will be our first acquisition into the North West province of South Africa. The Group anticipates this acquisition to initially add an additional 12% to group EBITDA. At the date of this report the transaction was still conditional upon various approvals, including the approval by the Competition Commission.

The directors are not aware of any matter, circumstance, results or cash flow arising since the end of the financial year to the date of this report that could have a material effect on the financial position of the Group.

10. Going concern

The consolidated annual financial statements have been prepared on the basis of accounting policies applicable to a going concern. This basis presumes that funds will be available to finance future operations and that the realisation of assets and settlement of liabilities, contingent obligations and commitments will occur in the ordinary course of business.

11. Special resolutions

The following special resolutions were passed during the course of the year at the annual general meeting of shareholders:

- Approval of financial assistance in terms of section 44 and 45 of the Companies Act.
- Non-executive director fees for the 12 months following the annual general meeting.
- General authority to approve the acquisition of shares in the company.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Statement of Profit or Loss and Other Comprehensive Income

Figures in R `000	Notes	Group 2022	Group 2021
Revenue	4	3,386,123	2,837,153
Cost of sales		(1,064,916)	(941,057)
Gross profit		2,321,207	1,896,096
Other income		203,131	114,904
Operating costs		(2,122,736)	(1,892,992)
Profit from operating activities	5	401,602	118,008
Impairment of non financial assets		-	(92,074)
Interest income	6	2,482	2,054
Finance costs	7	(126,019)	(127,334)
Share of profit from equity accounted investments		3,553	2,856
Profit / (loss) before tax		281,618	(96,490)
Income tax (expense) / credit	8	(33,926)	27,086
Profit / (loss) for the year		247,692	(69,404)
Other comprehensive income net of tax			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign currency translation reserve		3,778	(41,347)
Cash flow hedging reserve for interest rate hedging instrument		14,375	(14,195)
Total other comprehensive income / (loss)		18,153	(55,542)
Total comprehensive income / (loss)		265,845	(124,946)
Profit / (loss) for the year attributable to:			
Owners of parent		221,223	(73,324)
Non-controlling interests		26,469	3,920
		247,692	(69,404)
Total comprehensive income / (loss) attributable to:			
Owners of parent		241,484	(127,727)
Non-controlling interests		24,361	2,781
		265,845	(124,946)
Earnings per share attributable to owners of the parent during the year			
Basic and diluted earnings / (loss) per share (cents)	9	31.18	(10.33)

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Statement of Financial Position

Figures in R `000	Notes	Group 2022	Group 2021
Assets			
Non-current assets			
Property, plant and equipment	11	2,846,080	2,733,660
Right-of-use assets	14	185,168	197,458
Goodwill	10	308,528	302,545
Intangible assets	12	43,758	20,659
Investment in subsidiaries and associates	13	9,896	6,344
Deferred tax assets	15	80,691	77,206
		3,474,121	3,337,872
Current assets			
Inventories	16	73,582	76,617
Trade and other receivables	17	892,460	974,162
Current tax assets		10,782	17,574
Cash and cash equivalents	18	201,279	52,797
		1,178,103	1,121,150
Total assets		4,652,224	4,459,022
Equity and liabilities			
Equity			
Stated capital	19	426,006	426,006
Accumulated profits		1,596,857	1,365,123
Other reserves	20	161,042	140,781
Non-controlling interests		244,563	216,292
Total equity		2,428,468	2,148,202
Liabilities			
Non-current liabilities			
Deferred tax liabilities	15	230,491	221,454
Derivative financial liabilities	23	-	5,681
Lease liabilities	14	205,970	210,911
Long-term liabilities	21	989,763	1,021,167
Loans from non-controlling interests	22	21,921	18,782
		1,448,145	1,477,995
Current liabilities			
Provisions	25	104,574	83,402
Trade and other payables	24	491,936	455,150
Current tax liabilities		2,830	6,088
Current portion of derivative financial liabilities	23	4,358	18,643
Current portion of lease liabilities	14	10,697	9,324
Current portion of long-term liabilities	21	111,294	112,844
Loans from non-controlling interests	22	10,762	15,112
Bank overdraft	18	39,160	132,262
		775,611	832,825
Total equity and liabilities		4,652,224	4,459,022

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Statement of Cash Flows

Figures in R `000	Notes	Group 2022	Group 2021
Cash flows from operations			
Profit / (loss) for the year		247,692	(69,404)
Income tax		33,926	(27,086)
Interest income		(2,482)	(2,054)
Finance costs		126,019	127,333
Depreciation and amortisation		132,069	125,259
Impairment losses recognised in profit or loss		-	92,074
Income from associates		(3,553)	(2,236)
Loss on disposal of plant and equipment		33	953
Working capital changes:			
Decrease / (Increase) in inventories		8,638	(6,509)
Decrease in trade and other receivables		84,271	52,101
Increase in trade and other payables		36,349	21,003
Net cash flows from operations		662,962	311,434
Net cash flows from operating activities			
Finance costs		(124,654)	(127,333)
Interest income		2,482	2,054
Income taxes paid	26	(22,949)	(20,839)
Net cash flows from operating activities		517,841	165,316
Cash flows used in investing activities			
Cash flows used in obtaining control of subsidiaries or other businesses	29.2	(50,300)	-
Proceeds from sales of property, plant and equipment		231	382
Purchase of property, plant and equipment		(150,127)	(91,730)
- to maintain operating capacity		(124,709)	(107,645)
- to expand operating capacity		(41,198)	(7,605)
- instalment sale agreements (non-cash)		15,780	23,520
Purchase of intangible assets		(9,487)	(4,368)
Cash flows used in investing activities		(209,683)	(95,716)
Cash flows used in financing activities			
Loans paid		(59,198)	(61,777)
Lease liabilities		(10,348)	(10,766)
Dividend paid to non-controlling interests		(306)	(306)
Non controlling interests rights issue		453	-
Cash flows used in financing activities		(69,399)	(72,849)
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes			
		238,759	(3,249)
Effect of exchange rate changes on cash and cash equivalents		2,825	(1,228)
Cash and cash equivalents at beginning of the year		(79,465)	(74,988)
Cash and cash equivalents at end of the year	18	162,119	(79,465)

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Statement of Changes in Equity

Figures in R `000	Stated capital	Foreign currency translation reserve	Cash flow hedging reserve	Accumulated profits	Attributable to owners of the parent	Non-controlling interests	Total
Balance at 1 March 2020	426,006	198,503	(3,319)	1,438,447	2,059,637	213,817	2,273,454
(Loss) / profit for the year	-	-	-	(73,324)	(73,324)	3,920	(69,404)
Other comprehensive loss	-	(40,208)	(14,195)	-	(54,403)	(1,139)	(55,542)
Dividends paid to non-controlling interests	-	-	-	-	-	(306)	(306)
Balance at 1 March 2021	426,006	158,295	(17,514)	1,365,123	1,931,910	216,292	2,148,202
Profit for the year	-	-	-	221,223	221,223	26,469	247,692
Other comprehensive income / (loss)	-	5,886	14,375	-	20,261	(2,108)	18,153
Dividends	-	-	-	-	-	(306)	(306)
Acquisition of Howick Private Hospital Holdings (Pty) Ltd	-	-	-	-	-	14,295	14,295
Changes in ownership interests without loss of control	-	-	-	10,511	10,511	(10,079)	432
Balance at 28 February 2022	426,006	164,181	(3,139)	1,596,857	2,183,905	244,563	2,428,468
Notes	19						

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Accounting Policies

1. Basis of preparation and summary of significant accounting policies

These consolidated annual financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), comply with SAICA Financial Reporting Guides as issued by the Accounting Practices Committee, Financial Reporting Announcements issued by the Financial Reporting Standards Council and the Companies Act of South Africa. These policies have been consistently applied to all years presented, unless otherwise stated. They have been prepared on the historical cost basis, unless otherwise stated. The principal accounting policies incorporated are listed below.

The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that may affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Judgements made by management in the application of IFRS that have a significant effect on the financial statements, and significant estimates made in the preparation of these consolidated annual financial statements are disclosed in note 2.

The financial statements are presented in South African Rand (R), the functional currency of the Group and all amounts are rounded to the nearest thousand, except where otherwise indicated. Foreign currency exchange rates used in the preparation of converting into Rands are set out below:

	28/02/2022		28/02/2021	
	BWP Pula	USD Dollar	BWP Pula	USD Dollar
Closing rate	R1.33	R15.40	R1.39	R15.12
Average rate	R1.33	R14.86	R1.43	R16.50

1.1 Basis of consolidation

These financial statements are consolidated annual financial statements of Lenmed Investments Limited and its subsidiaries and associates. Control is achieved when the Group has powers over the investee, is exposed or has rights to variable returns from its investment with the investee and has the ability to use its power to affect its returns. If facts and circumstances indicate that there are changes to one or more elements of control, the Group shall reassess whether it controls the investee.

Subsidiaries

Subsidiaries are consolidated from the date on which the control is transferred to the Group and are no longer consolidated from the date that control ceases. The acquisition method of accounting is used to account for the acquisition of subsidiaries. The cost of an acquisition is measured as the fair value of the assets transferred, shares issued or liabilities assumed at the date of acquisition plus costs directly attributable to the acquisition. The excess of the cost of acquisition over the fair value of the net assets of the subsidiaries acquired is recorded as goodwill. If the cost of acquisition is less than the fair value of the net assets of the subsidiary acquired, the difference is recognised directly in the income statement. Inter-company transactions, balances and unrealised gains on transactions between Group companies are eliminated.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Accounting Policies

Basis of preparation and summary of significant accounting policies continued...

Non-controlling interests in subsidiaries are presented in the consolidated statement of financial position separately from the equity attributable to equity owners of the parent company. Non-controlling shareholders' interest may initially be measured at fair value or the non-controlling shareholders' proportionate share of the fair value of the acquiree's identifiable net assets. The choice of measurement basis is made on each acquisition individually. Subsequent to acquisition, the carrying amount of non-controlling interests is the amount of those interests at initial recognition plus the non-controlling interests' share of subsequent changes in equity. Total comprehensive income is attributed to non-controlling interests even if this results in the non-controlling having a deficit balance.

Associates

An associate is an entity over which the Group has significant influence and that is neither a subsidiary nor an interest in a joint venture. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies. The investment in an associate is initially recognised at cost and adjusted for the Group's share in the net assets of the investee after the date of acquisition. If the Group's share of losses of an associate equals or exceeds its interest in the associate, the Group discontinues recognising its share of further losses.

1.2 Revenue from contracts with customers

Revenue for hospital and related services rendered and medical consumables sold in the ordinary course of business is recognised at the consideration received or expected to be received for providing the services or goods specified in the contract with the patient net of indirect taxes and trade discounts.

Revenue is categorised into tariff and non-tariff revenue. Tariff revenue is from accommodation, equipment rental, theatre fees, professional and ward fees and is recognised over time when the service is rendered. Non-tariff revenue is from ethicals and medical consumables and is recognised at a point in time when consumed. Invoices raised are payable on presentation.

1.3 Other income

Rental income from operating leases is recognised on a straight-line basis over the term of the relevant lease.

Outpatient services income relates to emergency healthcare services provided which includes vehicle helicopter and air support together with a professional emergency healthcare team. Income is recognised as services are rendered at the consideration receivable in terms of the contract.

Dividends are recognised when the shareholders' right to receive payment is established.

Interest received is recognised on a time proportion basis, taking account of the principal amount outstanding and the effective rate over the period to maturity, when it is determined that such income will accrue to the Group.

Gains or losses on foreign currency translations of foreign subsidiary loans are recognised in profit and loss, where the loans do not form part of the net investment in the foreign operations, and in other comprehensive income when it does form part of the net investment.

1.4 Cost of sales

Cost of sales includes all costs of purchase. Inventory write-downs are included in cost of sales when recognised. Trade discounts and similar costs are deducted in determining the costs of purchases. Where the Group employs doctors and recognises revenue on their professional services rendered, the cost of employing these doctors is recognised as a cost of sale.

1.5 Inventories

Inventory is stated at the lower of cost or net realisable value on a weighted average basis. Cost comprises all costs of purchase and other costs which are incurred in bringing the inventory to its present location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs necessary to make the sale.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Accounting Policies

Basis of preparation and summary of significant accounting policies continued...

1.6 Tax

Current tax

The charge for current tax is based on the results for the year adjusted for items which are tax exempt or are not tax deductible. Tax is calculated using rates that have been enacted or substantively enacted by the reporting date.

Deferred tax

Deferred tax is provided on the liability method and is computed as the difference between the tax base and carrying amounts of assets and liabilities. Deferred tax liabilities are recognised for all taxable temporary differences. Deferred tax assets are recognised for deductible temporary differences as well as unused tax losses to the extent that it is probable that taxable profits will be available against which the deductible temporary difference can be utilised. The probability of taxable profits are calculated based on business plans which includes estimates and assumptions regarding economic growth, interest and competitive forecasts. The carrying amount of the deferred tax assets are reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are not recognised if they arise in the following situations: the initial recognition of goodwill; or the initial recognition of assets and liabilities that affect neither accounting nor taxable profit.

1.7 Leases

The Group assesses whether a contract is or contains a lease, at inception of the contract. The Group recognises a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short term leases (defined as leases with a lease term of 12 months or less), leases of low value assets and variable lease payments that do not depend on an index or rate. For these leases, the company recognises the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the lessee uses its incremental borrowing rate.

Lease payments included in the measurement of the lease liability comprise:

- Fixed lease payments; and
- Variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date.

The lease liability is presented as a separate line in the statement of financial position. The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made.

The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever:

- The lease term has changed;
- The lease payments change due to changes in an index or rate, in which cases the lease liability is remeasured by discounting the revised lease payments using an unchanged discount rate (unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used); or
- A lease contract is modified and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Accounting Policies

Basis of preparation and summary of significant accounting policies continued...

Right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated over the shorter period of lease term (ranging between 1 and 19 years) and useful life of the underlying asset (see note 1.9). If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. Depreciation is recorded from the commencement date of the lease.

Right-of-use assets are presented as a separate line in the consolidated statement of financial position.

Variable lease payments that do not depend on an index or rate are not included in the measurement of the lease liability and the right-of-use asset. The related payments are recognised as an expense in the period in which the event or condition that triggers those payments occurs.

Contingent rentals are recognised as expenses in the periods in which they are incurred.

1.8 Goodwill

Goodwill on acquisitions comprises the excess of the aggregate of the fair value of the consideration transferred, the fair value of any previously held interests, and the recognised value of the non-controlling interest in the acquiree over the net identifiable assets acquired and liabilities assumed at acquisition date.

Goodwill is carried at cost less accumulated impairment losses. Goodwill is tested for impairment annually. Gains and losses on the disposal of an entity include the carrying amount of goodwill relating to the entity sold.

To the extent that the fair value of the net identifiable assets of the entity acquired exceeds the cost of acquisition, the excess is recognised in profit and loss on acquisition date.

1.9 Property, plant and equipment

Property, plant and equipment are initially recorded at cost including any costs directly attributable to bringing the assets to the location and conditions necessary for them to be fully operation, less accumulated depreciation and any impairment losses.

The residual value represents the best estimate of the current recoverable amount of the asset at the end of its useful life.

Property, plant and equipment is depreciated to estimated residual value on a straight line basis over the asset's expected useful lives. Land is not depreciated. Buildings are depreciated to their estimated residual value.

The following are the current estimated useful lives:

Land	Indefinite
Buildings	50 years
Leasehold improvements	Written off over the period of lease
Plant & Equipment	5-20 years
Motor vehicles	5 years
Computer Equipment	3-8 years
Office Equipment	10-20 years
Furniture & Fittings	10-20 years

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Accounting Policies

Basis of preparation and summary of significant accounting policies continued...

Gains or losses on disposal of assets are calculated as the fair value of the consideration received less the carrying amount at the date of sale and are recognised in profit and loss.

1.10 Impairment of a non-financial asset

The carrying amounts of the assets other than deferred tax assets, inventory and financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, or when annual impairment testing for an asset is required, the recoverable amount is estimated as the higher of the net selling price and value-in-use. For goodwill and intangible assets that have an indefinite useful life the recoverable amount is estimated at least annually.

In assessing value-in-use, the expected future cash flows are discounted to present value using pre-tax discount rates that reflect current market assessments of the time value of money and the risk specific to the asset. An impairment loss is recognised whenever the carrying amount exceeds the recoverable amount. Impairment losses and reversals of impairment losses are separately disclosed in profit and loss.

A previously recognised impairment loss is reversed if there has been a change in the estimate used to determine the recoverable amount, however not to an amount higher than the carrying amount that would have been determined (net of depreciation) had no impairment loss been recognised in prior years. An impairment loss in respect of goodwill is not reversed.

1.11 Provisions

Provisions are recognised when the Group has a present legal or constructive obligation as a result of past events, for which it is probable that an outflow of economic benefits will occur, and when a reliable estimate can be made of the amount of the obligation. Where the effect of discounting is material, provisions are discounted. The discount rate used is a pre-tax rate that reflect current market assumptions of the time value of money and are risk specific where appropriate.

1.12 Employee benefits

Short-term employee benefits

The cost of all short-term benefits is recognised during the period in which the employee renders the related service.

The provisions for employee entitlements to wages, salaries and annual leave represent the amount which the Group has a present obligation to pay as a result of the employees' services provided during the reporting date. The provisions have been calculated at undiscounted amounts based on current wage and salary rates.

The expected cost of profit-sharing and bonus payments is recognised when there is a present legal or constructive obligation to make such payments as a result of past events, and a reliable estimate of the obligation can be made. A present obligation exists when there is no realistic alternative but to make the payments.

Retirement benefits

The Group contribute to defined contribution funds on behalf of its employees. Contributions are charged against profit or loss as incurred.

When an employee has rendered service to an entity during a period, the contribution payable to a defined contribution plan in exchange for that service is recognised:

- As a liability, after deducting any contribution already paid. Where the contribution already paid exceeds the contribution due for service before the end of the reporting period, the excess is recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.
- As an expense, except where the amount is allowed as an inclusion in the cost of an asset.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Accounting Policies

Basis of preparation and summary of significant accounting policies continued...

1.13 Financial instruments

The Group classifies financial instruments on initial recognition as a financial asset, a financial liability or an equity instrument in accordance with the substance of the contractual arrangement.

Financial instruments are recognised in the statement of financial position at fair value when the Group becomes a party to the contractual provisions of the instrument. Direct transaction costs are included in the initial carrying value of the financial instrument except in the case of financial instruments classified at fair value through profit and loss, in which case the transaction costs are expensed as they are incurred.

The Group has divided its financial instruments into the classes based on the manner in which the financial instruments are managed and reported on for internal management purposes.

Cash and cash equivalents

Cash and cash equivalents are initially measured at fair value and subsequently measured at amortised cost. In the statement of cash flows, bank overdrafts are offset against cash and cash equivalents.

Working capital balances

These include trade and other receivables and trade and other payables which arise in the normal course of the Group's business.

Subsequent to initial measurement, the constituents of the above classes of financial instruments are measured as follows:

Trade and other receivables

Trade receivables are initially recognised at the transaction price and subsequently measured at amortised cost using the effective interest rate method and reduced by impairment losses.

The Group recognises lifetime Expected Credit Losses "ECL" for trade and other receivables. Under the simplified approach, the loss allowance is calculated over the lifetime of the asset. Trade receivables is disaggregated into major categories and the credit risk is assessed for each category. The ECL on these financial assets are estimated using a provision matrix based on the Group's historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate. Loss allowances are reviewed at the end of each reporting period.

Subsequent recoveries of amounts previously written off are recognised in profit and loss.

Trade and other payables

Trade and loans payables are initially measured at fair value and subsequently measured at their amortised cost using the effective interest rate method.

Hedge accounting

Hedge accounting is applied to financial assets and financial liabilities only where all of the following criteria are met:

- The hedging relationship consists only of eligible hedging instruments and eligible hedged items.
- At the inception of the hedge there is a formal designation and documentation of the hedging relationship and the Group's risk management objective and strategy for undertaking the hedge;
- The hedge relationship meets all of the hedge effectiveness requirements including that an economic relationship exists between the hedged item and the hedging instrument, the credit risk effect does not dominate the value changes, and the hedge ratio of the hedging relationship is the same as that resulting from the quantity of the hedged item that the entity actually hedges and the quantity of the hedging instrument that the entity actually uses to hedge that quantity of hedged item.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Accounting Policies

Basis of preparation and summary of significant accounting policies continued...

Cash flow hedges

The effective part of hedging instruments designated as a hedge of the variability in cash flows of interest rate risk arising from fixed interest rate swaps are measured at fair value with changes in fair value recognised in other comprehensive income and accumulated in the cash flow hedge reserve. The Group used this contract to fix the cost of debt on some long term loans. The ineffective portion of gains and losses on derivatives used to manage cash flow interest rate risk are recognised in profit or loss within finance expense or finance income.

Borrowings

Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortised cost, using the effective interest rate method. Any difference between proceeds (net of transaction costs) and the redemption value is recognised in profit or loss over the period of the borrowings as interest.

1.14 Intangible assets

Intangible assets are initially recognised at cost.

Intangible assets are considered for impairment if there is any reason to believe that impairment may be necessary. Factors taken into consideration include the economic viability of the asset itself and where it is a component of a larger cash-generating unit, the viability of the unit.

Intangible assets are amortised on a straight-line basis over their estimated useful lives. The amortisation methods and remaining useful lives are reviewed at least annually. The estimation of the useful lives of intangible assets is based on historic performance as well as expectations about future use and therefore requires a significant degree of judgement.

An intangible asset is regarded as having an indefinite useful life when, based on all relevant factors, there is no foreseeable limit to the period over which the asset is expected to generate net cash inflows. Amortisation is not provided for these intangible assets but they are tested for impairment annually.

Management agreement acquired as part of a business combination are recognised at their fair value at the date of acquisition, and are subsequently amortised on a straight-line based on the timing of projected cash flows of the contracts over the remaining period of the agreement. In other words, they have a finite useful life and are subsequently carried at cost less accumulated amortisation and impairment losses.

The assumptions regarding estimated useful lives for the 2022 financial year were as follows:

Computer software	5 years
Management agreement	61 months
Hospital licences	Indefinite

1.15 Contingencies and commitments

Contingent liabilities are a possible obligation whose existence will be confirmed by a future event or a present obligation which cannot be recognised because the probability of an outflow is remote or the amount cannot be measured reliably. Items are classified as commitments where the Group commits itself to future transactions, particularly in the acquisition of property, plant and equipment. Contingent liabilities are not recognised.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Accounting Policies

Basis of preparation and summary of significant accounting policies continued...

1.16 Share incentive scheme

The Group operates a cash-settled share incentive scheme, under which it receives services from employees as consideration for cash with the fair value of the employee services received being measured by reference to the estimated fair value at the grant date of equity instruments granted and is recognised as an expense over the vesting period. The estimated fair value of the option granted is calculated using the Black Scholes option pricing model. The total amount expensed is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied.

1.17 Foreign currency translation

Items included in the financial results of each entity are translated using the functional currency of that entity.

Foreign currency transactions

Income and expenditure transactions are translated into the functional currency of the entity at the rate of exchange ruling at the transaction date. Monetary assets and liabilities are translated into the functional currency of the entity at the rate of the exchange ruling at the reporting date. Foreign exchange gains or losses resulting from the translation and settlement of monetary assets and liabilities are charged to profit or loss, except when they relate to cash flow hedging activities in which case these gains or losses are recognised in other comprehensive income and included in the cash flow hedge accounting reserve in equity.

Foreign operations

The financial results of all entities that have a functional currency different from the presentation currency of their parent entity are translated into the presentation currency. Income and expenditure transactions of foreign operations are translated at the average rate of exchange for the year. All assets and liabilities, including fair value adjustments arising on acquisition, are translated at the rate of exchange ruling at the reporting date. Differences arising on translation are recognised in other comprehensive income and included in the foreign currency translation reserve in equity.

On consolidation, differences arising from the translation of the net investment in a foreign operation are recognised in other comprehensive income and included in the foreign currency translation reserve in equity.

On disposal of part or all of the investment, the proportionate share of the related cumulative gains or losses previously recognised in the foreign currency translation reserve in equity are included in determining the profit or loss on disposal of that investment charged to profit or loss.

Goodwill and fair value adjustments arising on the acquisition of a foreign operation are treated as assets and liabilities of the foreign operation and translated at the closing rate at each reporting date.

1.18 Earnings per share

The Group presents basic and diluted earnings per share (EPS) for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to the ordinary shareholders by the weighted average number of outstanding shares during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the dilutive effect of all share options granted to employees.

1.19 Headline earnings per share

Headline earnings per share are calculated on the headline earnings attributable to ordinary shareholders divided by the weighted average number of ordinary shares in issue during the year. Headline earnings are determined in accordance with the Headline Earnings Circular issued by the South African Institute of Chartered Accountants from time to time and effective as at year end.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Accounting Policies

2. Critical accounting estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Key sources of estimation uncertainty

2.1 *Deferred tax*

A deferred tax asset is recognised on unused tax losses adjusted for the current year to the extent that it is probable that future taxable profit will be available against which the unused tax losses can be utilised. The Group considered the following criteria in assessing the probability that taxable profit will be available against which the unused tax losses can be utilised:

- Whether the entity has sufficient taxable temporary differences relating to the same taxation authority and the same taxable entity which will result in taxable amounts against which the unused tax losses can be utilised;
- Whether it is probable that the entity will have taxable profits before the unused tax losses expire; and
- Whether the unused tax losses result from identifiable causes which are unlikely to recur.

To the extent that it is not probable that taxable profits will be available against which the unused tax losses or unused tax credits can be utilised, the deferred tax asset is not recognised. To determine the probability that taxable profit will be available against which the unused tax losses can be utilised, the Group has reviewed its forecasts for the foreseeable future and compared that to its total tax losses.

2.2 *Financial instruments*

Impairment of financial assets

The Group recognises lifetime Expected Credit Loss (ECL) for trade and other receivables. The expected credit losses on these financial assets are estimated using a provision matrix based on the Group's historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecast at the reporting date, including time value of money where appropriate.

The Group regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes past due.

Measurement and recognition of expected credit losses

The measurement of expected credit losses is a function of the probability of default, loss given default (i.e. the magnitude of the loss if there is a default) and the exposure at default. The assessment of the probability of default and loss given default is based on historical data adjusted by forward-looking information such as:

- The credit control performance of each hospital.
- Discussions with significant medical aid funded.
- The impact of macro and micro economic factors on private debtors.
- Improvement to credit control and employment of more skilled resources.

As for the exposure at default, for financial assets, this is represented by the assets' gross carrying amount at the reporting date, the Group's understanding of the specific future financing needs of the debtors, and other relevant forward-looking information.

For financial assets, the expected credit loss is estimated as the difference between all contractual cash flows that are due to the Group in accordance with the contract and all the cash flows that the Group expects to receive, discounted at the original effective interest rate where applicable.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Accounting Policies

Critical accounting estimates and judgements continued...

2.3 Determination of lease terms for determining lease liability

The lease arrangements which one of the Group's subsidiaries is a party to, contain renewal clauses which depend on the future performance of the subsidiary. In determining whether the subsidiary will exercise its renewal option, management makes judgements on whether the subsidiary is likely to meet the financial conditions required in order to extend the lease term.

2.4 Residual values and useful lives of items of property, plant and equipment

Buildings

The Group's estimate of the useful life of buildings is 50 years due to the specialised nature of the buildings. The residual value of buildings is determined by management taking into account significant judgements applied to various factors and external information available.

Plant and equipment

Due to the specialised nature of the Group's plant and equipment, the residual value attached to these assets has been estimated to be nil with useful lives of between 3 and 20 years.

2.5 Goodwill

Goodwill is tested for impairment at each statement of financial position date. The recoverable amounts of cash-generating units have been estimated based on value-in-use calculations.

2.6 Share-based payments

The fair value is calculated using the Black Scholes option pricing model. Please refer to note 24 for assumptions used in the model.

2.7 Control over subsidiaries

An assessment of control was performed by the Group based on whether the Group has the practical ability to direct the relevant activities unilaterally. In making the judgement, the relative size and dispersion of other vote holders, potential voting rights held by them or others, rights from other contractual arrangements were considered. After the assessment, the Group concluded that they had a dominant voting interest to direct the relevant activities of the subsidiaries and it would take a number of vote holders to outvote the Group, therefore the Group has control over the subsidiaries.

2.8 Fair value measurements and valuation processes

The Group measures some of its assets and liabilities at fair value at each reporting date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The fair value of an asset or liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Accounting Policies

Critical accounting estimates and judgements continued...

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1: Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2: Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.
- Level 3: Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

3. Changes in accounting policies and disclosures

Standards and interpretations effective and adopted in the current year

No relevant new, revised or amended standards were implemented during the financial reporting period ended 28 February 2022.

Standards and interpretations effective not yet adopted

At the date of authorisation of these consolidated annual financial statements, the following relevant standards and interpretations were in issue but not yet effective. The directors have considered the impact of the below standards and interpretations and believe their effect to be immaterial.

Standard	Annual financial period ending applicable to Lenmed:
IFRS 3 - Reference to the Conceptual Framework	28 February 2023
IFRS 9 - Annual Improvements to IFRS Standards 2018–2020	28 February 2023
IAS 16 - Property, Plant and Equipment — Proceeds before Intended Use	28 February 2023
IAS 37 - Onerous Contracts — Cost of Fulfilling a Contract	28 February 2023
IAS 8 - Definition of accounting estimates	29 February 2024
IAS 1 - Classification of Liabilities as Current or Non-Current and disclosure of accounting policies	29 February 2024

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
4. Revenue		
An analysis of revenue is as follows:		
<i>Private healthcare services</i>		
Non-tariff	1,001,803	692,871
Tariff	2,384,320	2,144,282
Total revenue	3,386,123	2,837,153
There were no outstanding performance obligations at year end.		
5. Profit before interest and taxation		
<i>Income</i>		
Outpatient services income	40,320	21,501
Rental income	65,566	51,841
(Loss)/profit on foreign currency transactions	(4,909)	1,843
<i>Expenses</i>		
Depreciation and amortisation on intangible assets, plant and equipment	112,244	102,164
Depreciation on right-of-use assets	19,825	23,095
Employee benefit expenses	1,122,936	893,157
Loss on disposal of property, plant and equipment	33	953
<i>Short-term leases, low value leases and leases that do not depend on an index or rate</i>		
Property	25,399	22,303
Equipment	23,370	12,568
Other	7,928	14,335
	<u>56,697</u>	<u>49,206</u>
6. Interest income		
Interest received	<u>2,482</u>	<u>2,054</u>
7. Finance costs		
Long-term loans	94,330	92,704
Lease liabilities	14,160	16,019
Instalment sales agreements	117	562
Bank overdraft	17,412	18,049
Total finance costs	126,019	127,334

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
8. Income tax expense / (credit)		
8.1 Income tax recognised in profit or loss:		
Current tax		
Current year	29,179	6,025
Prior year adjustment	(2,877)	-
Total current tax	26,302	6,025
Deferred tax		
Originating and reversing temporary differences	16,443	(30,988)
Arising from prior period adjustments	(8,819)	(2,123)
Total deferred tax	7,624	(33,111)
Total income tax expense / (credit)	33,926	(27,086)
8.2 The income tax for the year can be reconciled to accounting profit / (loss) as follows:		
Income tax calculated at 28.0%	28.00%	28.00%
Tax effect of		
Under provision in prior year	(4.15%)	(2.20%)
Disallowed expenditure	0.35%	0.71%
Income not taxable	(0.38%)	(1.89%)
Lower foreign tax rate	(0.79%)	(0.60%)
Unrecognised deferred tax asset	(10.98%)	(18.07%)
Impairment	0.00%	22.12%
Effective tax rate	12.05%	28.07%
8.3 Estimated tax losses		
Utilised in the deferred tax balance	351,928	340,659
Not recognised as a deferred tax asset	-	110,457
Unused tax losses available for set-off against future taxable income	351,928	451,116
9. Earnings / (loss) per share		
9.1 Basic earnings / (loss) per share		
The earnings and weighted average number of ordinary shares used in the calculation of basic earnings per share are as follows:		
Profit / (loss) for the year attributable to owners of the company for continuing operations	221,223	(73,324)
Weighted average number of ordinary shares used in the calculation of basic earnings per share	709,534	709,534

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
<i>Earnings / (loss) per share continued...</i>		
Basic and diluted earnings / (loss) per share (cents)	31.18	(10.33)
9.2 Headline earnings per share		
Headline earnings is calculated as follows:		
Profit for the year attributable to owners of the company from continuing operations	221,223	(73,324)
<i>Adjusted for:</i>		
Loss on disposal of property, plant and equipment	33	953
Impairment of goodwill	-	10,343
Impairment of buildings	-	81,731
Total tax effects of adjustments	(9)	(4,747)
Headline earnings from continuing operations	221,247	14,956
Weighted average number of ordinary shares used in the calculation of headline earnings per share		
	709,534	709,534
Headline earnings per share (cents)	31.18	2.11

10. Goodwill

10.1 Reconciliation of changes in goodwill

	Goodwill
Reconciliation for the year ended 28 February 2022	
Balance at 1 March 2021	
At cost	312,888
Accumulated impairment	(10,343)
Net book value	302,545
Movements for the year ended 28 February 2022	
Acquisitions through business combinations - Howick (refer to note 29)	5,983
Goodwill at the end of the year	308,528
Closing balance at 28 February 2022	
At cost	318,871
Accumulated impairment	(10,343)
Net book value	308,528
Reconciliation for the year ended 28 February 2021	
At cost	312,888
Movements for the year ended 28 February 2021	
Impairment loss recognised in profit or loss	(10,343)
Goodwill at the end of the year	302,545

Goodwill relates to the excess of the purchase price consideration over the fair value of the assets and liabilities of the following business acquisitions:

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
<i>Goodwill continued...</i>		
Lenmed Health Laverna	5,125	5,125
Lenmed Health Shifa	6,939	6,939
Lenmed Health Kathu Private Hospital	10,378	10,378
Lenmed Ethekwini Hospital and Heart Centre	280,103	280,103
Howick Private Hospital	5,983	-
	<u>308,528</u>	<u>302,545</u>

An annual impairment test is conducted on goodwill. Management determines the recoverable amounts of cash-generating-units as being the higher of net selling price or value-in-use. In the absence of an active market, value-in-use is used to determine the recoverable amount. A traditional method of discounting management's best estimate of future cash flows attributable to the cash-generating-unit has been applied to determine the value-in-use. A growth rate has been applied to the cash flow streams to take into account the effect of inflation. Management has based its cash flow projections covering a 5 year period.

Key assumptions used in the calculation of the discount rate:

- R213 rate was yielding 9.88% as at 28 February 2022 (R186 rate - 2021: 7.31%)
- A market risk premium of 7.2% (2021: 10%), given the unlisted nature of the Group.
- Beta of 0.7 (2021: 0.7) is appropriate in the current environment and based on the defensive nature of the Group.

Value-in-use calculations have been based on a subjective pre-tax discount rate of between 13% and 17.5% (2021: 15.9% and 18.3%).

The net present value of these forecasts support the value of goodwill indicated above. Management has based their assumptions on past experience and external sources of information.

Sensitivity

The Group has made estimates and assumptions in respect of impairment testing of cash generating units as detailed above.

Discount rate:

Had the pre-tax discount rate been increased by 1%, the recoverable amounts of the goodwill of any the cash generating units would still exceed the carrying value.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

11. Property, plant and equipment

Balances at year end and movements for the year

	Land	Buildings	Leasehold improvements	Plant and equipment	Motor vehicles	Furniture and fittings	Office equipment	Computer equipment	Total
Reconciliation for the year ended 28 February 2022									
Carrying value at 1 March 2021	298,487	1,976,405	217	376,526	1,662	50,517	1,385	28,461	2,733,660
Movements for the year ended 28 February 2022									
Additions from acquisitions	-	41,664	-	104,579	1,284	9,448	945	7,987	165,908
Acquisitions through business combinations	1,500	21,070	-	6,276	-	450	155	9	29,460
Increase (decrease) through net exchange differences	1,435	4,233	-	7,593	16	437	(76)	(498)	13,140
Depreciation	-	(9,713)	(15)	(71,625)	(482)	(7,639)	(309)	(6,073)	(95,856)
Disposals	-	(26)	-	(71)	-	(134)	-	-	(231)
Property, plant and equipment at the end of the year	301,422	2,033,633	202	423,278	2,480	53,079	2,100	29,886	2,846,080
Closing balance at 28 February 2022									
At cost	301,422	2,135,836	7,670	945,798	4,880	111,515	5,033	94,532	3,606,686
Accumulated depreciation and impairment	-	(102,203)	(7,468)	(522,520)	(2,400)	(58,436)	(2,933)	(64,646)	(760,606)
Net book value	301,422	2,033,633	202	423,278	2,480	53,079	2,100	29,886	2,846,080
Reconciliation for the year ended 28 February 2021									
Carrying value at 1 March 2020	298,690	2,069,562	648	376,498	1,130	56,175	2,017	23,994	2,828,714
Movements for the year ended 28 February 2021									
Additions from acquisitions	2,935	12,598	39	76,542	1,286	4,859	66	13,848	112,172
Decrease through net exchange differences	(3,138)	(15,796)	-	(9,192)	(94)	(3,353)	-	(415)	(31,988)
Depreciation	-	(8,228)	(470)	(66,057)	(660)	(7,094)	(698)	(8,966)	(92,173)
Impairment loss recognised in profit or loss	-	(81,731)	-	-	-	-	-	-	(81,731)
Disposals	-	-	-	(1,265)	-	(70)	-	-	(1,335)
Property, plant and equipment at the end of the year	298,487	1,976,405	217	376,526	1,662	50,517	1,385	28,461	2,733,660

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

Property, plant and equipment continued...

Closing balance at 28 February 2021

At cost	298,487	2,085,676	7,670	804,600	4,673	101,576	10,256	94,887	3,407,825
Accumulated depreciation and impairment	-	(109,271)	(7,453)	(428,074)	(3,011)	(51,059)	(8,871)	(66,426)	(674,165)
Net book value	298,487	1,976,405	217	376,526	1,662	50,517	1,385	28,461	2,733,660

Certain property, plant and equipment have been used as security for financing facilities. Refer to note 21.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

12. Intangible assets

Reconciliation of changes in intangible assets

	Computer software	Hospital licences	Management agreement	Total
Reconciliation for the year ended 28 February 2022				
Carrying value as at 1 March 2021	18,180	2,479	-	20,659
Movements for the year ended 28 February 2022				
Additions other than through business combinations	9,487	-	-	9,487
Acquisitions through business combinations	-	-	30,000	30,000
Amortisation	(13,438)	-	(2,950)	(16,388)
Intangible assets at the end of the year	14,229	2,479	27,050	43,758
Closing balance at 28 February 2022				
At cost	50,402	2,479	30,000	82,881
Accumulated amortisation	(36,173)	-	(2,950)	(39,123)
Net book value	14,229	2,479	27,050	43,758
Reconciliation for the year ended 28 February 2021				
Carrying value as at 1 March 2020	23,803	2,479	-	26,282
Movements for the year ended 28 February 2021				
Additions	4,368	-	-	4,368
Amortisation	(9,991)	-	-	(9,991)
Intangible assets at the end of the year	18,180	2,479	-	20,659
Closing balance at 28 February 2021				
At cost	40,915	2,479	-	43,394
Accumulated amortisation	(22,735)	-	-	(22,735)
Net book value	18,180	2,479	-	20,659

Intangibles are valued as per note 1.14. All intangibles are tested annually for impairment. The estimation of the indefinite useful life of hospital licences is based on historic performance as well as expectations about future use. Software relates to the Group's deployment of SAP software at its various facilities. Management agreement relates to a hospital management agreement acquired in the new business combination with Halcom Management Services Limited.

The recoverable amount of the hospital licence is determined by projecting a future cash flow expected to be generated by the intangible asset. The present value of these cash flows is determined using an appropriate discount rate.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

13. Investment in subsidiaries and associates

13.1 Composition of the group

Information about the incorporation of the Group is as follows:

Name of subsidiary	% shareholding
Direct	
Lenmed Health (Pty) Ltd	100%
Lenmed Health Africa (Pty) Ltd	100%
Lenmed Health Finance Company (Pty) Ltd	100%
Indirect	
Ahmed Kathrada Private Hospital (Pty) Ltd	100%
Lenmed Health Daxina Private Hospital (Pty) Ltd	100%
Lenmed Health Management Company (Pty) Ltd	100%
Lenmed Health Nursing College (Pty) Ltd	100%
Lenmed Health Properties (Pty) Ltd	100%
Lenmed Health Randfontein Private Hospital (Pty) Ltd	100%
Lenmed Health Shifa (Pty) Ltd	100%
Lenmed Health Zamokuhle (Pty) Ltd	100%
Maputo Private Hospital Limitada	100%
Mozambique Private Laboratory Limitada	100%
LMPH Real Estate, Lda	100%
Nu-Yale Trust	100%
Royal Hospital and Heart Centre (Pty) Ltd	100%
Halcom Management Services Limited	100%
Lenmed Howick Pharmacy (Pty) Ltd	100%
Howick Private Hospital Holdings (Pty) Ltd	99%
Howick Private Hospital (Pty) Ltd	99%
Lenmed Health Laverna (Pty) Ltd	93%
Lenmed Ethekwini Hospital and Heart Centre (Pty) Ltd	77%
Lenmed Health Bokamoso Private Hospital (Pty) Ltd	70%
Lenmed Health Kathu Private Hospital (Pty) Ltd	67%
Lenmed Health Kathu Properties (Pty) Ltd	60%

All the subsidiaries have a place of business within the Republic of South Africa except for Lenmed Health Bokamoso Private Hospital (Pty) Ltd (Incorporated in Botswana), Maputo Private Hospital Limitada (Incorporated in Mozambique), Mozambique Private Laboratory Limitada (Incorporated in Mozambique), LMPH Real Estate, Lda (Incorporated in Mozambique) and Halcom Management Services Limited (Incorporated in Seychelles).

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

Investment in subsidiaries and associates continued...

13.2.1 Summarised financial information for subsidiaries with material non-controlling interests before inter-company eliminations

	Lenmed Ethekekwini Hospital and Heart Centre (Pty) Ltd	Lenmed Health Bokamoso Private Hospital (Pty) Ltd
% of interest and voting rights held by non-controlling interests	23%	30%
At 28 February 2022		
<i>Extract from statement of financial position</i>		
Non-current assets	879,572	235,699
Current assets	157,404	419,570
Non-current liabilities	(179,867)	(197,334)
Current liabilities	(112,912)	(235,716)
Accumulated non-controlling interests at the end of the reporting period	<u>(172,504)</u>	<u>(68,523)</u>
<i>Extract from statement of comprehensive income</i>		
Revenue	731,788	523,421
Profit or loss	76,962	38,405
Profit for the year allocated to non-controlling interests	<u>17,701</u>	<u>11,522</u>
<i>Extract from statement of cash flows</i>		
Cash inflow from operating activities	111,415	53,396
Cash outflow from investing activities	(43,248)	(19,879)
Cash (outflow)/inflow from financing activities	(39,083)	2,627
Net cash inflow	<u>29,084</u>	<u>36,144</u>
At 28 February 2021		
<i>Extract from statement of financial position</i>		
Non-current assets	848,053	261,996
Current assets	137,432	316,194
Non-current liabilities	(197,225)	(204,425)
Current liabilities	(121,548)	(182,226)
Accumulated non-controlling interests at the end of the reporting period	<u>(154,812)</u>	<u>(59,142)</u>
<i>Extract from statement of comprehensive income</i>		
Revenue	591,707	433,023
Profit or loss	25,722	(4,843)
Profit for the year allocated to non-controlling interests	<u>5,913</u>	<u>(1,453)</u>

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

Investment in subsidiaries and associates continued...

13.2.1 Summarised financial information for subsidiaries with material non-controlling interests before inter-company eliminations continued

Extract from statement of cash flows

Cash inflow from operating activities	63,111	78,593
Cash outflow from investing activities	(28,513)	(29,348)
Cash outflow from financing activities	(35,480)	(37,532)
Net cash (outflow)/inflow	(882)	11,713

Group 2022	Group 2021
-----------------------	-----------------------

The Group's investment in Lenasia Renal Care (Pty) Ltd and Renal Care Holdings (Pty) Ltd are accounted for under the equity method of accounting.

Lenasia Renal Centre (Pty) Ltd.

The Group owns 30% of Lenasia Renal Care Centre (Pty) Ltd, a renal dialysis unit situated adjacent to Ahmed Kathrada Private Hospital.

Opening balance	2,036	1,966
Share of associate earnings	677	370
Dividends received	-	(300)
Closing balance	2,713	2,036

Renal Care Holdings (Pty) Ltd

The Group owns 40% of Renal Care Holdings (Pty) Ltd, a renal dialysis holding company.

Opening balance	4,308	2,142
Share of associate earnings	2,876	2,486
Dividends received	-	(320)
Closing balance	7,184	4,308

Investment in associates

9,897	6,344
--------------	--------------

The directors are of the opinion that the fair value of the above investments exceeds its carrying value.

14. Lease liabilities

14.1 Amounts recognised in the statement of financial position

Right-of-use assets

Buildings	185,168	197,458
-----------	---------	---------

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
Lease liabilities continued...		
<i>Reconciliation of right-of-use asset:</i>		
Opening carrying value	197,458	222,273
Additions	14,821	3,595
Depreciation	(19,825)	(23,095)
Reassessment of lease contract	-	(1,730)
Foreign currency exchange difference	(7,286)	(3,585)
Carrying value	<u>185,168</u>	<u>197,458</u>
Right-of-use-assets represent the present value of future minimum lease payments discounted at a rate of between 6.5% and 9.5% (2021: 6.5% and 9.5%) after taking the lease term ranging between 1 and 19 years into account.		
Lease liabilities		
Non-current lease liability	205,970	210,911
Current portion of lease liability	10,697	9,324
	<u>216,667</u>	<u>220,235</u>
<i>Maturity analysis of future lease payments outstanding at the reporting date:</i>		
Total	216,667	220,235
Total future lease payments	335,975	356,596
Due within 1 year	24,939	22,562
Due between 2 and 5 years	95,786	110,517
Greater than 5 years	215,250	223,517
Total future finance costs	119,308	136,361
Due within 1 year	14,242	14,249
Due between 2 and 5 years	46,764	61,238
Greater than 5 years	58,302	60,874
Total lease liability	216,667	220,235
Due within 1 year	10,697	8,313
Due between 2 and 5 years	49,022	49,279
Greater than 5 years	156,948	162,643
<i>Reconciliation of lease liabilities</i>		
Opening carrying value	220,235	231,571
Additions	14,821	3,595
Lease payments	(10,348)	(10,766)
Foreign currency exchange difference	(8,041)	(4,165)
Carrying value	<u>216,667</u>	<u>220,235</u>

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
<i>Lease liabilities continued...</i>		
14.2 Amounts recognised in the statement of profit or loss and other comprehensive income		
Depreciation		
Buildings	19,825	23,095
Other expenses and gains		
Interest expense	14,160	16,019
Short-term lease expenses	56,701	49,206
14.3 Amounts recognised in the statement of cash flows		
Cash flow from operations		
- Interest paid	(14,160)	(16,019)
Cash flow from financing activities		
- Lease liabilities	(10,348)	(10,766)
15. Deferred tax		
15.1 The analysis of deferred tax assets and deferred tax liabilities is as follows:		
Deferred tax assets:		
- Deferred tax assets to be recovered	80,691	77,206
	80,691	77,206
Deferred tax liabilities:		
- Deferred tax liability to be recovered	(230,491)	(221,454)
	(230,491)	(221,454)
Net deferred tax liabilities	(149,800)	(144,248)

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

Deferred tax continued...

15.2 Reconciliation of deferred tax asset

	Property, plant and equipment	Provisions	Assessed losses	Other*	Lease liability	Prepaid expense	Cash flow hedging reserve	Total
Opening balance at 1 March 2021	(39,527)	25,352	82,544	266	4,970	(3,210)	6,811	77,206
(Charged) / credited to profit or loss	(25,299)	22,317	18,423	(14,642)	2,052	(1,438)	-	1,413
Credited to other comprehensive income	-	-	-	-	-	-	(5,591)	(5,591)
Acquisition of subsidiary	(3,426)	413	9,007	-	-	-	-	5,994
Exchange difference	-	-	1,669	-	-	-	-	1,669
Closing balance at 28 February 2022	(68,252)	48,082	111,643	(14,376)	7,022	(4,648)	1,220	80,691
Opening balance at 1 March 2020	(6,263)	20,668	54,597	715	2,332	(802)	1,291	72,538
(Charged) / credited to profit or loss	(33,264)	4,684	28,948	(449)	2,638	(2,408)	-	149
Credited to other comprehensive income	-	-	-	-	-	-	5,520	5,520
Exchange difference	-	-	(1,001)	-	-	-	-	(1,001)
Closing balance at 28 February 2021	(39,527)	25,352	82,544	266	4,970	(3,210)	6,811	77,206

Reconciliation of deferred tax liability

	Property, plant and equipment	Provisions	FV in Step acquisition	Lease smoothing adjustment	Assessed loss	Prepaid expense	Other*	Total
Opening balance at 1 March 2021	(192,554)	6,362	(46,866)	(1,657)	18,993	(1,489)	(4,243)	(221,454)
(Charged) / credited to profit or loss	(9,992)	5,649	49	1,657	(8,845)	564	1,881	(9,037)
Closing balance at 28 February 2022	(202,546)	12,011	(46,817)	-	10,148	(925)	(2,362)	(230,491)
Opening balance at 1 March 2020	(218,447)	14,115	(46,866)	(1,728)	2,431	(1,127)	(2,794)	(254,416)
Credited/ (charged) to profit or loss	25,893	(7,753)	-	71	16,562	(362)	(1,449)	32,962
Closing balance at 28 February 2021	(192,554)	6,362	(46,866)	(1,657)	18,993	(1,489)	(4,243)	(221,454)

*Other comprises of lease liability and foreign currency translation on loan.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
<i>Deferred tax continued...</i>		
15.3 Deferred tax assets where utilisation is dependent on future taxable profits		
Amount of the deferred tax asset raised where utilisation is dependent on future taxable profits	98,540	96,073
Deferred tax assets not recognised because of uncertainty of availability of future taxable profits amounts to nil (2021: R30.928 million)		
16. Inventories		
Inventories comprise:		
Merchandise	74,636	93,599
Allowance for obsolete stock	(1,054)	(16,982)
	73,582	76,617
Allowance for obsolete stock		
Balance at beginning of year	16,982	327
Allowance raised	-	16,655
Stock written off	(15,928)	-
Balance at end of year	1,054	16,982
17. Trade and other receivables		
17.1 Trade and other receivables comprise:		
Trade receivables	1,006,036	1,015,414
Allowance for expected credit loss	(230,773)	(177,671)
Trade receivables - net	775,263	837,743
Sundry debtors	53,457	57,040
Doctors rental	22,389	22,494
Allowance for expected credit loss	(23,102)	(13,937)
Sundry debtors - net	52,744	65,597
RAF prefunding	36,660	45,698
Allowance for expected credit loss	(5,512)	(8,739)
RAF prefunding - net	31,148	36,959
Prepaid expenses	20,581	18,890
Deposits	12,724	11,042
Value added tax	-	3,931
Total trade and other receivables	892,460	974,162

The carrying value of trade and other receivables approximated their fair value due to the short-term nature of these receivables.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
<i>Trade and other receivables continued...</i>		
17.2 Movements in allowance for expected credit loss		
At the beginning of the year	200,347	147,914
Impairment raised	94,526	76,160
Written off during the year	(35,486)	(23,727)
At the end of the year	259,387	200,347

The Group determines the trade receivables and RAF prefunding expected credit loss allowance using the provision matrix approach. The provision rates are based on days past due for groupings of various customer categories with similar loss patterns (mainly by customer type). The customer types are Medical Aid funders, Government, Workmen's Compensation, Private patients and the Road Accident Fund. Credit risk per category is determined using past information and experience with debtors as well as expectations of the future recoverability of amounts due from debtors. Trade and other receivables are written off when there is no reasonable expectation of recovery. Debtors written off are subject to enforcement activities under the Group's debtor collection procedures, taking into account legal advice where appropriate. Any recoveries made are recognised in profit or loss. The loss allowance is summarised as:

Group

Allowance for expected credit losses for trade receivables and RAF prefunding:

Less than 30 days	8,834	5,725
30-59 days	5,640	8,132
60-89 days	6,308	8,148
90-119 days	6,341	7,155
120 days and over	209,162	157,250
	<u>236,285</u>	<u>186,410</u>

Weighted average allowance for expected credit losses rate for trade receivables and RAF prefunding:

Less than 30 days	3 %	3 %
30-59 days	8 %	11 %
60-89 days	9 %	14 %
90-119 days	13 %	16 %
120 days and over	44 %	55 %
	<u>24 %</u>	<u>20 %</u>

During the year, the method of analysing historical data used in the estimation of expected credit losses for trade receivables and RAF prefunding was refined. This change in estimate resulted in a R3.971 million increase in the allowance for expected credit loss.

18. Cash and cash equivalents

18.1 Cash and cash equivalents included in current assets:

Cash

Cash on hand	1,297	2,402
Balances with banks	199,982	50,395
	<u>201,279</u>	<u>52,797</u>

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
<i>Cash and cash equivalents continued...</i>		
18.2 Overdrawn cash and cash equivalents included in current liabilities		
Bank overdrafts	(39,160)	(132,262)
Current assets	201,279	52,797
Current liabilities	(39,160)	(132,262)
	162,119	(79,465)

Favourable cash balances to the value of R55.762 million (2021: R29.682 million) have been ceded to Rand Merchant Bank as security for facilities provided.

19. Issued capital

Authorised and issued share capital

Authorised

1 000 000 000 (2021: 1 000 000 000) ordinary shares at no par value.

Issued

709 533 909 ordinary shares at no par value (2021: 709 533 909 ordinary shares) 426,006 426,006

The directors are authorised, in terms of the company's Memorandum of Incorporation, to issue and allot any of the unissued share capital for any purpose and upon such terms and conditions as they deem fit.

20. Reserves

Cash flow hedging reserve	(3,139)	(17,514)
Foreign currency translation reserve	164,181	158,295
Total reserves	161,042	140,781

Cash flow hedging reserve

The effective portion of gains and losses on interest rate swaps used to manage cash flow interest rate risk are recognised in other comprehensive income and accumulated in the cash flow hedging reserve. Refer to note 23 for further information.

Foreign currency translation reserve

This reserve exists due to exchange differences arising on translation of assets and liabilities of the Group's foreign subsidiaries. Refer to note 13.1 for the list of foreign subsidiaries.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
21. Long term liabilities		
21.1 Mortgage bonds		
<i>Rand Merchant Bank</i>	1,044,561	1,067,690
These loans are secured by a first ranking mortgage bond over the Group's land and buildings with a carrying amount of R1.910 billion (2021: R1.863 billion) and a notarial bond of movable assets with a carrying value of R449.083 million (2021: R389.777 million). Interest has been charged at rates linked to JIBAR. The loan is split in 4 facilities. Facility A is a 5 year term loan with 4 years remaining and with a balance outstanding of R300 million. Interest repayable quarterly and capital repayable every 6 months. Facility B is a 5 year term loan with 4 years remaining and with a balance outstanding of R650 million. Interest is payable quarterly with no capital repayments until the end of the term where the full capital is meant to be repaid. Facility C is a 5 year term loan with 4 years remaining and with a balance outstanding of R65 million. Interest is payable quarterly with no capital repayments until the end of the term where the full capital is meant to be repaid. Facility D is USD denominated loan with interest payable quarterly. The loan is repayable in 3 months. The USD balance outstanding as at 28 February 2022 is USD1.919 million (2021: USD3.485 million). The Group hedges a portion of its interest rate risk by using interest rate swaps exchanging variable rate interest for fixed rate interest - refer to note 23.		
<i>First National Bank Limited</i>	27,972	34,999
These loans from First National Bank are secured by land and buildings with a carrying amount of R87.216 million (2021: R87.052 million) (refer to note 11). Interest has been charged at rates linked to prime. This loan is repayable in monthly instalments of R1.198 million (2021: R1 million).		
	<u>1,072,533</u>	<u>1,102,689</u>
Non-current portion of long term liabilities	967,972	1,008,753
Current portion of long term liabilities	104,561	93,936
	<u>1,072,533</u>	<u>1,102,689</u>
21.2 Instalment sales agreements		
<i>Wesbank, a division of FirstRand Bank Ltd</i>	28,524	31,322
Repayable in monthly instalments of R1.265 million (2021: R1.339 million). Interest has been charged at rates of interest linked to the prime lending rate. Secured by plant and equipment with a book value of R45.974 million (2021: R54.368 million).		
	<u>28,524</u>	<u>31,322</u>
Non-current portion of instalment sales agreements	21,791	12,414
Current portion of instalment sales agreements	6,733	18,908
	<u>28,524</u>	<u>31,322</u>

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
22. Loans from non-controlling interests		
Loans from non-controlling interests comprise:		
<i>ATM Healthcare (Pty) Ltd</i>	20,146	18,782
The loan is unsecured, has no fixed terms of repayment but will not be paid within the next 12 months and bears interest at prime rate.		
<i>Howick Holdings Hospital (Pty) Ltd</i>	1,775	-
The loan is unsecured, has no fixed terms of repayment but will not be paid within the next 12 months and bears no interest.		
<i>Lenmed Ethekwini Hospital and Heart Centre (Pty) Ltd non-controlling shareholders</i>	10,762	15,112
These loans are unsecured, bears no interest and are expected to be repaid within 12 months.		
	32,683	33,894
Non-current liabilities	21,921	18,782
Current liabilities	10,762	15,112
	32,683	33,894
23. Derivative financial liabilities		
Derivates designated as hedging instruments		
Interest rate swaps - cash flow hedge	4,358	24,324
Reconciliation of interest rate swaps		
Opening balance	24,324	4,609
Fair value through other comprehensive income	(14,375)	14,195
Deferred tax on fair value adjustment	(5,591)	5,520
Closing balance	4,358	24,324
Non-current portion of derivative financial liabilities	-	5,681
Current portion of derivative financial liabilities	4,358	18,643
	4,358	24,324

The Group manages a portion of its cash flow interest rate risk by using variable to fixed interest rate swaps. Gains and losses recognised in the cash flow hedging reserve in equity on interest rate swap contracts as at 28 February 2022 will be released to profit and loss as the related interest expense is recognised. The interest rate swaps expire on 31 May 2022 and relate to a notional amount of R750 million worth of borrowings from Rand Merchant Bank with the 3 month JIBAR fixed at an average rate of 6.55%. The 3 month JIBAR rate at year end was 3.97% (2021: 3.34%).

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
24. Trade and other payables		
Trade and other payables comprise:		
Trade creditors	467,721	414,841
Cash settled share based payments	3,009	951
Other payables	11,110	18,708
Value added tax	10,096	20,650
Total trade and other payables	491,936	455,150

Cash-settled share based payments

This is made up of three allocations of share appreciation rights (SARs):

1) Nil (2021: 7.700 million) SARs

9.600 million SARs were issued on 1st of August 2018 to three executive directors and fifteen members of senior management, at a price of R3.56 each. As at 28 February 2022, the rights had vested (2021:7.700 million SARs were in issue).

2) 5.600 million SARs (2021: 8.750 million) SARs

9.800 million SARs were issued on 1st of August 2019 to three executive directors and sixteen members of senior management, at a price of R3.71 each. As at 28 February 2022, 5,600 million (2021: 8.750 million) SARs were in issue. The reduction from the prior is due to the senior management attrition during the year.

3) 9.250 million SARs (2021: 9.650 million) SARs

9.650 million SARs were issued on 1st of August 2020 to two executive directors and twenty two members of senior management, at a price of R2.73 each. As at 28 February 2022, 9.250 million (2021: 9.650 million) SARs were in issue. The reduction from the prior is due to the senior management attrition during the year.

4) 11.200 million SARs

11.200 million SARs were issued on 1st of August 2021 to two executive directors and twenty three members of senior management, at a price of R2.77 each.

The Group has determined that the allocation should be accounted for as a cash-settled share-based payment transaction. The fair value of the SARs was calculated using the Black Scholes option pricing model. The amount recognised in the annual financial statements for the current year, in accordance with IFRS 2: Share-based payments, is an expense accrual of R2.057 million (2021: (R1.549 million — expense reversal)).

The assumptions used in determining the fair value of the SARs granted are summarised below:

	2	3	4
Last determined price as at 28 February 2022	R 2.77	R 2.77	R 2.77
Last determined price as at 29 February 2021	R 2.94	R 2.94	R 2.94
Risk-free rate	7.88%	7.88%	7.88%
Volatility	37 %	37 %	37 %
Dividend yield	0 %	0 %	0 %
Long-term inflation	6 %	6 %	6 %

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

Trade and other payables continued...

The risk-free rate of 7.88% (2021: 7.31%) has been assumed based on the prevailing return on a five-year RSA Government Bond as at year end.

The volatility of 37% (2021: 13%) was determined based on the historic volatility of the Group's share price over the previous year.

The carrying value of trade and other payables approximated their fair value due to the short-term nature of these payables.

25. Provisions

25.1 Provisions comprise:

Provisions for employee benefits	97,165	66,846
Other provisions	7,409	16,556
	104,574	83,402

25.2 Reconciliation for provisions

	Leave pay provision	Bonus Provision	Other provisions	Total
Balance at 1 March 2021	41,882	24,964	16,556	83,402
Increase in existing provisions	6,263	47,164	6,054	59,481
Provisions utilised	(6,870)	(15,750)	(15,171)	(37,791)
Increase (decrease) through net exchange differences	(353)	(135)	(30)	(518)
Balance at 28 February 2022	40,922	56,243	7,409	104,574
Balance at 1 March 2020	23,342	21,651	20,917	65,910
Increase in existing provisions	36,272	24,194	-	60,466
Provisions utilised	(17,732)	(20,881)	(4,361)	(42,974)
Balance at 28 February 2021	41,882	24,964	16,556	83,402

26. Income tax paid

Amounts (payable)/ receivable at the beginning of the year	11,486	(2,997)
Amounts (receivable)/ payable at the end of the year	(7,952)	(11,486)
Taxation (expense)/credit	(33,926)	27,086
Less deferred tax included in taxation expense	7,624	(33,111)
Foreign exchange movements	(181)	(331)
	(22,949)	(20,839)

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

27. Related parties

27.1 Related parties transactions

Transactions and balances between the Group and its subsidiaries, which are related parties of the Group, have been eliminated on consolidation.

The Group paid rentals to a non-subsidiary related party property company amounting to R2.017 million (2021: R1.811 million). The directors deem this rental to be market-related.

The remuneration and benefits received by the directors are disclosed in note 27.2

Entity name	Relationship	Transaction	2022	2021
Central City Investments (Pty) Ltd	Common director	Rental paid	2,017	1,811

27.2 Compensation paid to or receivable by directors and prescribed officers

Name	Fees paid	Salaries and guaranteed remuneration	Bonuses	Total remuneration
2022				
Mr P Devchand	-	2,080	-	2,080
Mr A Devchand	-	4,700	4,465	9,165
Mr F J Meiring	-	3,728	3,495	7,223
Mr M G Meehan	582	-	-	582
Ms B Harie	546	-	-	546
Ms N V Simamane	548	-	-	548
Prof B D Goolab	493	-	-	493
Dr G Goolab	496	-	-	496
Total compensation paid to or receivable by directors and prescribed officers	2,665	10,508	7,960	21,133
2021				
Mr P Devchand	-	2,000	-	2,000
Mr A Devchand	-	4,700	1,410	6,110
Mr F J Meiring	-	3,585	1,076	4,661
Mr M G Meehan	509	-	-	509
Ms B Harie	492	-	-	492
Ms N V Simamane	492	-	-	492
Prof B D Goolab	474	-	-	474
Dr G Goolab**	234	-	-	234
Total compensation paid to or receivable by directors and prescribed officers	2,201	10,285	2,486	14,972

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

Related parties continued...

* The bonuses disclosed are based on the performance for the period ended 28 February 2022 but paid after the financial year end.

The bonuses disclosed are based on the performance for the period ended 28 February 2021 but paid after the financial year end.

** Dr G Goolab was appointed on the 1st of August 2020.

28. Contingent liabilities

Certain Compensation for Occupational Injuries and Diseases (COID) debtors are factored between 83% and 84% of their original value. The factoring houses have recourse should they not be able to recover the debt. The total funds received but still open to recourse amounted to R10.040 million as at reporting date (2021: R14.559 million).

Within the framework of the annual review of contingent liabilities, medical malpractice contingent liabilities for a total amount of R17.220 million (2021: R8.800 million) have been identified at 28 February 2022. The Group does not recognise contingent liabilities in the statement of financial position until future events indicate that it is probable that an outflow of resources will take place and a reliable estimate can be made, at which time a provision is raised. A provision has been created of R4.556 million (2021: R7.200 million) for current and pending legal cases and reflected within other provisions (note 25). The Group is not aware of any other current or pending legal cases that would have a material adverse effect on the Group.

29. Business combinations

29.1 Details of acquisition

Name of acquiree	Principal activity	Date of acquisition	Proportion of voting equity interests acquired
Howick Private Hospital Holdings (Pty) Limited	Hospital	01/03/2021	50.04
Halcom Management Services Limited	Management services	01/09/2021	100.00

The primary reasons for acquiring Howick Private Hospital Holdings (Pty) Limited and Halcom Management Services Limited were to expand the Group's footprint in KwaZulu Natal and in Africa outside of South Africa respectively. Control was obtained by holding a majority shareholding in each company.

The Group subsequently acquired an additional 49.28% shares during the 2022 financial year increasing the shareholding in Howick Private Hospital Holdings to 99.32%.

29.2 Consideration transferred

	Howick Private Hospital Holdings (Pty) Limited	Halcom Management Services Limited	Total
Cash transferred	20,300	30,000	50,300

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021	
<i>Business combinations continued...</i>			
29.3 Assets acquired and liabilities recognised at the date of acquisition			
	Howick Private Hospital Holdings (Pty) Limited	Halcom Management Services Limited	Total
Non-current assets			
Property, plant and equipment	29,460	-	29,460
Intangible assets	-	30,000	30,000
Deferred tax assets	5,994	-	5,994
Current assets			
Other current financial assets	153	-	153
Non-current liabilities			
Other non-current financial liabilities	(6,995)	-	(6,995)
Assets acquired and liabilities recognised at the date of acquisition	28,612	30,000	58,612

29.4 Goodwill arising on acquisition

	Howick Private Hospital Holdings (Pty) Limited	Halcom Management Services Limited	Total
Consideration transferred	20,300	30,000	50,300
Plus non-controlling interest	14,295	-	14,295
Less fair value of net assets acquired	(28,612)	(30,000)	(58,612)
Goodwill arising on acquisition	5,983	-	5,983

The goodwill of R5.983 million is attributable to the potential high profitability of the acquired business. It will not be deductible for tax purposes.

29.5 Non-controlling interests

Non-controlling interest recognised at acquisition date	14,295	-
---	--------	---

For the non-controlling interests in Howick, the Group elected to recognise the non-controlling interests at its proportionate share of the acquired net identifiable assets.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
-------------------	---------------	---------------

Business combinations continued...

29.6 Impact of acquisitions on the results of the group

	Howick Private Hospital Holdings (Pty) Limited	Halcom Management Services Limited
Revenue since acquisition included in results	36,292	13,893
Profit or loss since acquisition included in results	(10,651)	6,578
Group revenue had the business combination been included for the full year	3,386,123	3,400,016
Group profit or loss had the business combination been included for the full year	247,692	254,270

30. Financial risk management

This note explains the Group's exposure to financial risks and how these risks could affect the Group's future financial performance. Current year profit and loss information has been included where relevant to add further context.

The Group's financial liabilities comprise long-term liabilities, short-term liabilities, trade and other payables and bank overdrafts. The main purpose of these financial liabilities is to raise finance for the Group's operations. The Group has various financial assets such as loan accounts, trade receivables and cash and cash equivalents, which arise directly from its operations. The main risks arising from the Group's financial instruments are interest rate risk, credit risk, liquidity risk and foreign currency risk. These risks are managed as follows:

30.1 Interest rate risk

Interest rate risk is the risk that changes in the interest rate will affect the Group's income or value of its financial instruments. The Group is exposed to interest rate risk through its commitments in interest bearing borrowings, lease liabilities, cash and cash equivalents and instalment sale agreements. The Group enters into derivative interest rate swap instruments in order to mitigate a portion of its interest rate risk and applies hedge accounting where the effectiveness criteria are met.

Interest risk table

The following table demonstrates the sensitivity of profit before tax (through the impact on floating rate borrowings) to a possible change in interest rates, with all other variables held constant and without taking into account the hedging benefits of the interest rate swap referred to in note 23:

Group

Interest bearing loans payable	1,072,533	1,102,689
Instalment sale liabilities	28,524	31,322
Lease liabilities	216,667	220,235
Loans from non-controlling interests	20,146	18,782
Bank overdraft	39,160	132,262
	1,377,030	1,505,290

Sensitivity analysis

Increase of 100 basis points would result in a reduction in profit before tax of	(13,770)	(15,053)
Decrease of 100 basis points would result in an improvement in profit before tax of	13,770	15,053

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
-------------------	---------------	---------------

Financial risk management continued...

30.2 Credit risk

Credit risk is the risk of financial loss due to counterparties to financial instruments not meeting their contractual obligations.

The Group deposits surplus cash with major reputable banks with high credit standing and between various financial institutions to limit the exposure to any one counterparty.

The Group evaluates credit risk relating to customers using credit verification and independent rating procedures. Individual risk limits are set for patients without medical aid insurance. Services to customers without medical aid insurance are settled in cash or using major credit cards on discharge date as far as possible.

The Group applies the IFRS 9 simplified approach to measure expected credit losses which uses a lifetime expected loss allowance for all trade and other receivables.

To measure the expected credit losses, trade receivables and contract assets have been grouped based on shared credit risk characteristics and the days past due. The expected loss rates are based on the payment profiles of revenue over a period of more than 12 months and the corresponding historical credit losses experienced within the same period. The historical cost rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the patients to settle the receivables. The maximum exposure is the carrying amount as disclosed in trade and other receivables note 17.

30.3 Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due.

The Group manages liquidity risk by monitoring forecast cash flows and ensuring that adequate un-utilised borrowing facilities are available. In addition, the Group maintains a strong business relationship with its bankers.

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

Financial risk management continued...

30.3.1 Maturities of financial liabilities

The tables below analyse the Group's financial liabilities into relevant maturity groupings based on their contractual maturities for all non-derivative financial liabilities, and net and gross settled derivative financial instruments for which the contractual maturities are essential for an understanding of the timing of the cash flows.

The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant. For interest rate swaps the cash flows have been estimated using forward interest rates applicable at the end of the reporting period.

Contractual maturities of financial liabilities	Less than 1 year	Between 1 and 2 years	Between 2 and 5 years	Total contractual cash flows	Carrying amount
Year ended 28 February 2022					
Trade and other payables excluding non-financial liabilities (Note 24)	481,840	-	-	481,840	481,840
Derivatives (Note 23)	4,358	-	-	4,358	4,358
Lease liabilities (Note 14)	24,939	95,786	215,250	335,975	216,667
Mortgage bonds (Note 21)	170,645	164,408	977,157	1,312,210	1,072,533
Instalment sale agreements	6,733	23,816	-	30,549	28,524
Loans from non-controlling interests (Note 22)	10,762	23,432	-	34,194	32,683
Bank overdraft (Note 18)	39,160	-	-	39,160	39,160
Total	738,437	307,442	1,192,407	2,238,287	1,875,765

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

Financial risk management continued...

Year ended 28 February 2021

Trade and other payables excluding non-financial liabilities (Note 24)	434,500	-	-	434,500	434,500
Derivatives (Note 23)	18,643	-	5,681	24,324	24,324
Lease liabilities (Note 14)	22,562	110,517	223,517	356,596	220,235
Mortgage bonds (Note 21)	169,204	239,683	828,157	1,237,044	1,102,689
Instalment sale agreements	18,908	-	14,148	33,056	31,322
Loans from non-controlling interests (Note 22)	15,112	-	20,097	35,209	33,894
Bank overdraft (Note 18)	132,262	-	-	132,262	168,013
Total	811,191	350,200	1,091,600	2,252,991	2,014,977

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
<i>Financial risk management continued...</i>		
30.4 Capital management		
The Group's objectives when managing capital are to safeguard the entity's ability to continue as a going concern, so that it can continue to provide returns for shareholders and benefit for other stakeholders.		
The Group manages the capital structure in light of changes in business activities and economic conditions. In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares, or sell assets to reduce debt.		
The Group monitors risk to capital on the basis of the interest bearing debt to capital ratio. This ratio is calculated as net interest bearing debt divided by capital. Net interest bearing debt is calculated as total bank interest bearing debt excluding lease liabilities less cash and cash equivalents. Capital comprises all components of equity (i.e. ordinary shares, minority interest, retained earnings and other reserves).		
The debt to capital ratio at year end is as follows:		
Mortgage bonds	1,072,533	1,102,689
Instalment sale agreements	28,524	31,322
Total interest bearing debt	1,101,057	1,134,011
Cash and cash equivalents	-162,119	79,465
Net interest bearing debt	938,938	1,213,476
Total capital	2,428,468	2,148,202
Debt to capital ratio	39 %	56 %

30.5 Foreign currency risk

The Group is exposed to foreign currency risk through its offshore subsidiaries, Maputo Private Hospital SA (Maputo hospital), Lenmed Health Bokamoso Private Hospital (Pty) Ltd (Bokamoso hospital) and Halcom Management Services Limited (HMS) which have different functional currencies. A US dollar denominated long term loan exists at Maputo hospital, however revenue at the hospital is partially US dollar denominated, thus forming a natural hedge. The net working capital at Maputo hospital is denominated in Mozambican Meticaís. This amount is considered immaterial and no hedging takes place. To date, the Group has not suffered any material currency loss. Revenue at the Bokamoso hospital is denominated in Pula, also forming a natural hedge. Revenue and profits generated by this hospital are expected to be sufficient to settle the shareholders' loans over a maximum period of seven years. The Group does not formally hedge its foreign currency risk.

Foreign Currency Translation Reserve	164,181	158,295
---	----------------	----------------

Refer to Note 1 for the exchange rates used to translate its foreign operations.

Rand Merchant Bank USD denominated loan facility at year end was:

Loan

Valued in USD	1,919	3,485
Valued in Rands	29,561	52,698

Sensitivity analysis

If the Rand weakened by 10%, it would result in a decrease of profit before tax of:	(2,956)	(5,270)
---	---------	---------

If the Rand strengthened by 10%, it would result in an increase of profit before tax of:	2,956	5,270
--	-------	-------

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000

31. Financial assets

31.1 Carrying amount of financial assets by category

	At amortised cost	Total
Year ended 28 February 2022		
Trade and other receivables excluding non-financial assets (Note 17)	871,879	871,879
Cash and cash equivalents (Note 18)	201,279	201,279
	1,073,158	1,073,158

	At amortised cost	Total
Year ended 28 February 2021		
Trade and other receivables excluding non-financial assets (Note 17)	955,272	955,272
Cash and cash equivalents (Note 18)	52,797	52,797
	1,008,069	1,008,069

32. Financial liabilities

32.1 Carrying amount of financial liabilities by category

	Fair value through other comprehensive income	At amortised cost	Total
Year ended 28 February 2022			
Derivatives (Note 23)	4,358	-	4,358
Lease liabilities (Note 14)	-	216,667	216,667
Mortgage bonds (Note 21)	-	1,072,533	1,072,533
Instalment sale agreements	-	28,524	28,524
Loans from non-controlling interests (Note 22)	-	32,683	32,683
Trade and other payables excluding non-financial liabilities (Note 24)	-	481,789	481,789
Bank overdraft (Note 18)	-	39,160	39,160
	4,358	1,871,356	1,875,714

Year ended 28 February 2021			
Derivatives (Note 23)	24,324	-	24,324
Lease liabilities (Note 14)	-	220,235	220,235
Mortgage bonds (Note 21)	-	1,102,689	1,102,689
Instalment sale agreements	-	31,322	31,322
Loans from non-controlling interests (Note 22)	-	33,894	33,894
Trade and other payables excluding non-financial liabilities (Note 24)	-	434,500	434,500
Bank overdraft (Note 18)	-	132,262	132,262
	24,324	1,954,902	1,979,226

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
-------------------	---------------	---------------

Financial liabilities continued...

32.2 Fair value hierarchy

Financial liabilities that are measured at fair value on a recurring basis are as follows:

Group	Level 2
Year ended 28 February 2022	
Derivatives (Note 23)	4,358
Year ended 28 February 2021	
Derivatives (Note 23)	24,324

33. Comparative Figures

Certain comparative figures have been reclassified in the Statement of Financial Position to correctly account for the treatment of the estimated credit loss allowance on the sundry debtors that was previously disclosed as trade and other payables instead of being netted off against the sundry debtors.

The effects of the reclassification are as follows:

Statement of Financial Position

Trade and other payables	-	13,937
Trade and other receivables	-	(13,937)

34. Commitments

Capital commitments

The construction, renovation and upgrading of hospital buildings	20,891	640
The acquisition of plant and equipment	33,236	8,689
Software development	2,556	-
Acquisition of shares in Howick Private Hospital Holdings (Pty) Ltd	-	22,600
	56,683	31,929

35. Segment information

35.1 General information

Consistent with the Group's internal reporting, the chief operating decision maker, being the Executive Committee, views the Group's operating results as a single segment and makes decisions about resources to be allocated and assesses performance accordingly.

The IFRS 8 required information about the Group as a single segment for the profit or loss, including specified revenues and expenses, and assets and liabilities have already been disclosed elsewhere in these consolidated annual financial statements.

The revenue from external customers for groups of similar products and services are disclosed in note 4.

The following geographical information is reported on:

Lenmed Investments Limited and its subsidiaries

(Registration Number 1980/003108/06)

Consolidated Annual Financial Statements for the year ended 28 February 2022

Notes to the Consolidated Annual Financial Statements

Figures in R `000	Group 2022	Group 2021
<i>Segment information continued...</i>		
Revenues from external customers		
South Africa	(2,409,564)	(1,964,226)
Outside of South Africa	(976,559)	(872,927)
Group total revenues from external customers	(3,386,123)	(2,837,153)
Non-current assets other than financial instruments and deferred tax assets		
South Africa	2,750,677	2,613,055
Outside of South Africa	666,398	647,611
Group total non-current assets other than financial instruments and deferred tax assets	3,417,075	3,260,666

36. Events after the reporting date

All events subsequent to the date of the consolidated and separate annual financial statements and for which the applicable financial reporting framework which require adjustment or disclosure have been adjusted or disclosed.

During May 2022, the Group entered into an agreement to acquire 100% of Matlosana Medical Health Services (Pty) Ltd ("MMHS"), a Klerksdorp based group of hospitals. MMHS consists of 2 acute facilities (218 beds), a day hospital (20 beds) and a mental health facility (50 beds). The acquisition aligns well with our strategy to diversify across geographies as well as revenue streams and will be our first acquisition into the North West province of South Africa. The Group anticipates this acquisition to initially add an additional 12% to group EBITDA. At the date of this report the transaction was still conditional upon various approvals, including the approval by the Competition Commission.

The directors are not aware of any matter or circumstance arising since the end of the financial year to the date of this report that could have a material effect on the financial position of the company other than described above.